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Summary 
In recent decades, the association between sleep-disor-
dered breathing (SDB) and cardio- and cerebrovascular 
diseases (including hypertension, coronary heart dis-
ease and stroke) has been the focus of interest of both 
clinicians and researchers. A growing concern is the in-
creasing prevalence of SDB in the general population, 
which can be partly explained by the rise in obesity prev-
alence and population aging, as well as by the develop-
ment of enhanced diagnostic tools and approaches. Be-
cause of evidence of adverse long-term effects of SDB 
on cardiovascular morbidity and overall mortality, sys-
tematic screening for SDB should be considered for pop-
ulations at risk. The evidence of a long-term benefit of 
treatment for SDB, however, is still controversial and the 
best management approaches are still unclear. 
This article summarises available epidemiological data 
and focuses on the main pathophysiological mecha-
nisms linking SDB to cardio- and cerebrovascular disor-
ders. We will also give a critical overview of the current 
diagnostic procedures. The available treatment ap-
proaches and their prognostic effects on cardio- and cer-
ebrovascular health will be discussed in a second paper. 
Key words: sleep disordered breathing; sleep disorders; 
sleep apnoea; noninvasive ventilation; cardiovascular 
events; cerebrovascular events; outcome; cardiovascu-
lar morbidity and mortality 
Introduction 
Over the past several decades, the prevalence of 
sleep-disordered breathing (SDB) has been contin-
uously rising, and SDB, especially obstructive sleep 
apnoea (OSA), has become a common major health 
concern in industrialised countries [1–3]. Several 
factors are likely to have contributed to this in-
crease, including the growing obesity epidemic in 
our societies, demographic changes with an aging 
population suffering from more comorbidities, and 
a raising awareness of SDB as a widespread disease. 
All forms of SDB may disturb the natural architec-
ture of sleep, leading to excessive daytime sleepi-
ness, fatigue, decreased alertness during the daytime 
and impaired cognitive functioning. Even more im-
portantly, SDB, especially OSA, is a major risk fac-
tor for cerebro- and cardiovascular morbidity and 
mortality. 
This association between SDB and cerebro- and car-
diovascular diseases has recently been recognised 
by both clinicians and researchers. The growing ev-
idence suggesting a causal link between SDB and 
cerebro- and cardiovascular morbidity has led to re-
cent guidelines pertaining to SDB in the manage-
ment of acute stroke [4], congestive heart failure [5] 
and arterial hypertension [6]. However, SDB re-
mains underdiagnosed and undertreated, mainly be-
cause the clinical symptoms of SDB are nonspecific 
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and, in many cases, unrecognised even by the af-
fected patient [7]. 
We summarise available epidemiological data and 
focus on the main pathophysiological mechanisms 
linking SDB to cerebro- and cardiovascular compli-
cations. We also provide an overview of current di-
agnostic approaches. 
Definition of sleep-disordered breathing 
Basically, any alteration of respiration during sleep 
that goes beyond the physiological adaption during 
the transition from wakefulness to sleep may be 
considered as sleep disordered breathing [7–10]. 
Based on the underlying pathophysiological mech-
anisms, sleep-related breathing disorders are de-
fined and categorised, according to the third edition 
of the international classification of sleep disorders 
[8], into four main groups: 
1. Obstructive sleep apnoea (OSA) 
2. Central sleep apnoea (CSA) 
3. Sleep-related hypoventilation disorder 
4. Sleep-related hypoxaemia disorder 
OSA is characterised by repetitive episodes of com-
plete (apnoea) or partial (hypopnoea) collapse of the 
upper airways during sleep, with maintained respir-
atory drive and respiratory effort. It results from 
various causes of upper airway collapse such as an 
anatomically narrow upper airway due to obesity, 
and bony or soft tissue structures. Upper airway re-
sistance or obstruction is generally exacerbated by 
muscle relaxation during sleep. By definition, OSA 
may be diagnosed if more than five obstructive res-
piratory events occur per hour of sleep, even if clin-
ically asymptomatic [8]. Therefore, from a clinical 
perspective, it is important to distinguish OSA from 
obstructive sleep apnoea syndrome (OSAS), the lat-
ter requiring the presence of clinical daytime and/or 
sleep-related symptoms, such as excessive sleepi-
ness, in addition to obstructive respiratory events 
(OSAS = OSA + clinical symptoms). This discrim-
ination has clinical implications because treatment 
of asymptomatic OSA is usually recommended only 
if the apnoea-hypopnoea-index (AHI, mean number 
of apnoeas and hypopnoeas per hour of sleep) is 
>15/h, or in the presence of relevant cardiovascular 
comorbidities, whereas in symptomatic patients 
(OSAS) initiation of therapy should be considered 
in all cases [8, 11]. 
In central sleep apnoea (CSA) the upper airway re-
mains patent. CSA is characterised by a reduction 
or a cessation of the airflow due to absent or reduced 
respiratory effort related to an impairment of the 
central respiratory regulation and/or respiratory 
muscle alteration. According to the third edition of 
the International Classification of Sleep Disorders 
(ICSD-3), the polysomnographic diagnostic criteria 
of CSA include three signs: the number of central 
apnoeas and/or hypopnoeas is >5/h of sleep, the to-
tal number of central events exceeds 50% of the to-
tal number of apnoeas/hypopnoeas, and the respira-
tory pattern shows Cheyne-Stokes respiration [8]. In 
adults, CSA includes several subgroups of disor-
ders, namely primary CSA, central sleep apnoea 
with and without Cheyne-Stokes respiration, and 
CSA due to medication or substances [12]. CSA 
may also develop at high altitude (CSA due to high 
altitude periodic breathing), an adaptive reaction as-
sociated with high-altitude hypocapnic alkalosis 
that is completely reversible when the individual re-
turns to sea level. CSA may also occur secondary to 
neurological disorders such as ischaemic stroke or 
cerebral haemorrhage where the respiratory centre 
in the brain stem is affected. Treatment-emergent 
CSA (formerly known as complex sleep apnoea) is 
another separate pattern of CSA that may develop 
in patients treated with positive airway pressure for 
OSA [8]. Sleep-related hypoventilation disorders 
are characterised by an abnormal nocturnal increase 
in the arterial partial pressure of carbon dioxide 
(PaCO2) due to decreased or impaired ventilation at 
night, either an increase of at least 10 mm Hg above 
awake values to 50 mm Hg for at least 10 minutes, 
or an increase to above 55 mm Hg for at least 10 
minutes [8]. 
The category of sleep-related hypoxaemia disorder 
was introduced to distinguish cases with sustained 
periods of significant hypoxaemia during sleep in 
the absence of other predefined SDB or hypoventi-
lation. 
Different types of SDB can overlap in the same pa-
tient. Also, the features of both obstructive and cen-
tral events can be found within the same respiratory 
episodes, when initially the respiratory effort is ab-
sent with the subsequent resumption. In these cases, 
mixed SDB is often diagnosed [13, 14]. 
Epidemiology of sleep-disordered 
breathing in cerebro- and cardiovascu-
lar diseases 
The most comprehensive data on SDB epidemiol-
ogy are available for OSA. The first large-scale pop-
ulation-based study from the USA, published in 
1993, showed that 9% of females and 24% of males 
in a middle-aged population present with an AHI 
>5/h, and 2 and 4%, respectively, suffer from symp-
tomatic OSAS [1].  
Swiss Medical Weekly · PDF of the online version · www.smw.ch   Page 3 of 16 
Published under the copyright license "Attribution - Non-Commercial - No Derivatives 4.0".  
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html. 
 
Table 1: The prevalence of SDB in various cardiovascular diseases and co-morbidities and adjusted odds/hazard ratios for 
the presence of these diseases in patients with SDB, mainly OSA. 
Pathology Prevalence of SDB Odds/hazard ratio  Ref. 
Arterial hypertension AHI 5/h: 58–74% 
AHI  15/h: 10–30% 
1.33–1.96  [2, 26–31] 
Resistant arterial hypertension AHI  5/h: 88% 
AHI 10/h: 60–83% 
AHI 30/h: 26–32%  
 [32, 33] 
Coronary artery disease (including acute myo-
cardial infarction, post-revascularisation pa-
tients) 
AHI 5/h: 83% 
AHI 10/h: 30–64% 
AHI 15/h: 64% 
1.27–3.1*  
 
[15, 16, 34–37] 
Congestive heart failure AHI 10/h: 72% 
AHI 15/h: 60–64% 
AHI 20/h: 53% 
AHI 30/h: 36% 
1.13–2.38† [13–16, 38–40] 
Heart rhythm and conduction disorders AHI 5/h: 60–66% 
AHI 10/h: 59% 
AHI 15/h: 14–47% 
AHI 30/h: 20–27% 
 [41–44] 
Atrial fibrillation AHI 5/h: 70–74% 
AHI 10/h: 49% 
AHI 15/h: 25–43% 
AHI 30/h: 13% 
2.18–3.29‡  [21, 39, 45–48] 
Stroke  AHI 5/h: 79–86% 
AHI 15/h: 35–40%  
AHI 30/h: 30% 
1.76–1.97 
 
[7, 15, 34, 49–52] 
Asymptomatic carotid stenosis AHI 10/h: 69%   [53] 
Pulmonary hypertension AHI 10/h: 60% 
AHI 15/h: 42% 
 [54–56] 
Obesity AHI 5/h: 8–78% 
AHI 15/h: 2–35% 
 [57, 58] 
Diabetes mellitus AHI 5/h: 60–63% 
AHI 15/h: 26–37% 
AHI 30/h: 10–12% 
1.43–2.30§  [2, 22, 59–61] 
Chronic kidney disease AHI 5/h: 54% 
AHI 15/h: 32–39% 
AHI 30/h: 6% 
 [62, 63] 
Haemodialysis AHI 10/h: 89% 
AHI 15/h: 50%  
 [64–67] 
AHI = apnoea/hypopnoea index; OSA = obstructive sleep apnoea; SDB = sleep-disordered breathing 
* Dose-dependent, the highest risk was observed in males aged <70 years.  
† Dose-dependent; in men, the adjusted hazard ratio of incident heart failure was 1.13 per 10 AHI units increase, 1.58 for AHI 30/h vs AHI 
<5/h, no association in woman 
‡ AHI >5/h; in multivariate analysis only the lowest oxygen desaturation was associated with atrial fibrillation (hazard ratio 3.29 per 1% de-
crease) 
§ Adjusted odds ratio for AHI 15/h vs <5/h 
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These data were revised by Peppard et al. in 2013, 
and a significant increase in SDB prevalence during 
the previous two decades was established. Accord-
ing to Peppard et al., 26% of the general middle-
aged population is affected by OSA and a rise, rang-
ing from 14 to 55% depending on gender and age of 
the subgroups, was observed [3]. This increase in 
OSA prevalence has also been reported from Euro-
pean countries. Based on data from a Swiss cohort 
including 2121 randomly selected subjects (mean 
age 57, range 40–85 years) from the city of Lau-
sanne, the SDB rates are estimated to be 60% in fe-
males and 83% in males (based on the presence of 
an AHI of 5/h), and 23 and 49%, respectively 
(based on a more stringent definition with an AHI 
15/h) [2]. As described earlier, elderly vs younger 
subjects and males vs females showed higher rates. 
Recently, studies demonstrated that the prevalence 
of relevant SDB is much higher in individuals with 
known cerebro- and cardiovascular events [15–18] 
and reaches values up to 50 to 90% in specific co-
horts [7, 19–21]. This was confirmed in pooled pop-
ulations in later meta-analyses [20]. This might im-
ply a direct association between SDB and cerebro- 
and cardiovascular morbidity. However, proving 
that SDB can independently cause cerebro- and car-
diovascular diseases remains a difficult issue, be-
cause most cerebro- and cardiovascular diseases 
share common risk factors with SDB, such as obe-
sity, male sex, age, smoking, or metabolic disorders 
[22–25]. Further, more severe SDB is associated 
with a higher prevalence of cardiovascular diseases, 
indicating a dose-dependent association also present 
after a multivariate adjustment for major cardiovas-
cular risk factors [15]. Interestingly, the type and 
distribution of SDB may vary in different diseases 
(table 1) with OSA (AHI 10/h) being commonly 
seen in systemic hypertension [11, 68, 69], coronary 
artery disease [34, 70], heart rhythm disorders [21, 
41], pulmonary hypertension [54] and stroke [7, 15, 
20, 49, 71]. In contrast, CSA is predominantly seen 
in patients with congestive heart failure, especially 
with left-ventricular systolic dysfunction (in up to 
30–50%), typically with CSR that is characterised 
by cyclic fluctuations in breathing in a waxing-wan-
ing (crescendo-decrescendo) mode, and in stroke 
patients (up to 25–30% in acute stroke) [7, 38, 71–
73]. 
Sleep-disordered breathing and arterial 
hypertension 
A causal association between OSA and arterial hy-
pertension was first suggested over 30 years ago, 
making it one of the most investigated and well-rec-
ognised relationships between OSA and a vascular 
comorbidity [74]. OSA is observed in up to 30 to 
50% of all hypertensive individuals and in more 
than 80% of all patients suffering from drug-re-
sistant arterial hypertension [11, 75]. The most com-
monly observed blood pressure features in OSA pa-
tients include elevated diastolic blood pressure, noc-
turnal hypertension and a non-dipping circadian 
blood pressure profile. Moreover, OSA (AHI 15/h) 
is recognised as one of the most prevalent causes of 
treatment-resistant hypertension; in a high-risk co-
hort, severe OSA was associated with a four-fold in-
crease in the prevalence of resistant elevated blood 
pressure despite intensive antihypertensive treat-
ment, even after adjustment for the major cardiovas-
cular risk factors [68]. However, despite the grow-
ing evidence supporting this association, there are 
still some unanswered questions. The trials address-
ing the antihypertensive effects of continuous posi-
tive airway pressure (CPAP) used as sleep apnoea 
treatment are controversial. An antihypertensive ef-
fect of CPAP therapy for OSA has been demon-
strated in a recent meta-analysis, but it was rather 
modest reaching only ˗2 to ˗3 mm Hg and was more 
profound for systolic and nocturnal blood pressure 
values [76, 77]. In a prospective observational study 
of 1889 participants followed for more than 11 
years, Marin et al. demonstrated that CPAP prevents 
new-onset hypertension in treatment-compliant pa-
tients (hazard ratio 0.71, 95% confidence interval 
[CI ] 0.53–0.94]) compared with control subjects 
with AHI <5/h, and the protective effect was ob-
served despite an increase in body mass index 
(BMI) [26]. However, this protective effect is not 
observed in asymptomatic (e.g., non-sleepy) OSA 
patients [78]. 
Sleep-disordered breathing and stroke / 
cerebrovascular disease 
Current data demonstrate a strong association be-
tween SDB and ischaemic stroke, although the ex-
act underlying mechanisms are still not completely 
elucidated. The prevalence of SDB (AHI 5/h) in 
stroke survivors significantly exceeds that in the 
general population and reaches 50 to 86% (AHI 
≥30/h: 30%). Stroke localisation and lesion volume 
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are discussed as potential influencing factors. How-
ever, no convincing evidence has until now been 
provided, and the influence of particular cerebral to-
pographies are controversial [7, 49, 50, 79–81]. 
CSA with or without Cheyne-Stokes respiration is 
found in patients with lesions in the central auto-
nomic network (e.g., medulla oblongata), suggest-
ing a link to cardiorespiratory central control [7]. 
Some studies showed an association between SDB 
and nocturnal onset of cerebrovascular events, in-
cluding the wake-up stroke that comprises up to 25 
to 30% of all acute cerebrovascular events. Thus, 
wake-up stroke patients show more severe sleep ap-
noea than those with daytime stroke onset, and the 
frequency of moderate-to-severe SDB (AHI >15/h) 
is higher in wake-up stroke patients [82–84]. How-
ever, in the recently published SLEEP-TIGHT 
study, the frequencies of SDB in wake-up stroke 
and non-wake-up stroke patients were similar [84], 
and the causal relationship is still uncertain. 
SDB tends to improve from the acute to the sub-
acute phase of stroke, and this may be more the case 
for CSA than OSA [79, 85–87]. Various reasons for 
the improvement of SDB are discussed, including 
the amelioration of neurological deficits, a higher 
level of physical activity and less time spent in the 
supine position during sleep. 
As mentioned above, comorbid cardiovascular dis-
eases and metabolic dysregulations frequently seen 
in OSA patients may all promote stroke. However, 
OSA and CSA with or without Cheyne-Stokes res-
piration are frequently encountered in acute and 
chronic stroke patients (with OSA being the pre-
dominant type), even in the absence of other classi-
cal cardiovascular or metabolic risk factors [7, 49, 
88]. Therefore, SDB itself may increase the risk of 
stroke independently of these factors. Some studies 
provided evidence of the dominant role of hypoxae-
mia (in particular when its duration exceeds 10% of 
sleep) in incident stroke in subjects with SDB [89]. 
The risk of stroke in SDB was confirmed to be 
three- to four-fold higher after adjustment for the 
major cardiovascular risk factors [90, 91]. Interest-
ingly, some studies noted gender-specific differ-
ences, with a significantly higher impact of OSA on 
stroke incidence in men, but not in women. 
There is growing evidence that SDB adversely af-
fects early stroke outcome and is associated with a 
worse functional outcome in the acute and subacute 
phases [7, 80]. Presence of SDB is also an independ-
ent predictor of higher mortality rates after stroke, 
and mortality increases in proportion to the AHI val-
ues [51, 92]. A recently published systematic review 
focused on the effects of SDB after cerebrovascular 
events, and demonstrated that OSA is a risk factor 
for vascular event recurrence and all-cause mortal-
ity in post-stroke patients [93]. However, the effects 
of positive airway pressure (PAP) treatment on 
post-stroke outcomes are controversial [94–96]. At 
the same time, the prognostic cut-offs of SDB se-
verity, and therefore the indication for treatment in-
itiation after stroke, are not established and further 
investigations are required. An international multi-
centre study (SAS-CARE) addressing these issues 
recently completed patient recruitment, and first re-
sults will be published in 2017 [97]. A second pro-
spective interventional randomised trial (eSATIS), 
evaluating early adaptive servoventilation treatment 
in acute stroke patients with severe SDB, was 
started in 2015 (ClinicalTrials.gov Identifier: 
NCT02554487) [98]. 
SDB has increasingly been recognised as a risk fac-
tor for cognitive impairment and dementia. As-
sumed mechanisms underlying this association in-
clude cerebral hypoperfusion, endothelial dysfunc-
tion, impaired cerebral vasomotor reactivity and 
neuroinflammation resulting in cerebral small ves-
sel disease and subsequent white matter lesions, 
grey matter loss and neurodegenerative processes 
[99]. 
Because of the relationship between sleep disorders 
and stroke, as well as the need for multidisciplinary 
approaches in this field, a taskforce on “Sleep and 
Stroke” was initiated by four European societies 
(European Respiratory Society, European Stroke 
Organisation, European Academy of Neurology and 
European Sleep Research Society) in 2016. The 
taskforce is chaired by Professor C.L. Bassetti, Pro-
fessor W. Randerath, and Dr V. Papavasileiou, and 
aims at developing position statements based on re-
viewed evidence. 
Sleep-disordered breathing and coro-
nary artery disease 
As for other cerebro- and cardiovascular diseases, in 
patients with coronary artery disease the prevalence 
of OSA is higher than in the normal population [35, 
70]. In 1999, Peker et al. reported a prevalence of 
OSA (defined as a respiratory disturbance index of 
>10/h) of 30% in patients admitted with an acute 
coronary syndrome, and identified an independent 
association between OSA and coronary artery dis-
ease in a multivariate model (odds ratio 3.1, 95% CI 
1.2–8.3) [35]. Recent studies reported a wide range 
of SDB prevalence in patients with coronary artery 
disease, from 26 to 69% depending on the investi-
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gated population and the criteria to establish the di-
agnosis of OSA, such as values of AHI, scoring cri-
teria [70, 100]. 
The interaction between SDB and coronary artery 
disease also manifests in higher mortality rates if 
both entities are concomitantly present in a patient. 
A decade ago, Gami et al. (2005) had already shown 
that SDB patients are more likely to die suddenly 
during the classical sleeping hours (from 10 p.m. to 
6 a.m.), in contrast to the general population and 
subjects without sleep apnoea [45]. Almost 10 years 
later, the same group retrospectively evaluated a 
sample of US residents consisting of 10 701 adults, 
and demonstrated that OSA was a strong predictor 
of sudden cardiac death at night. Moreover, the 
magnitude of the risk was associated with several 
parameters characterising OSA severity, including 
AHI (20/h), mean nocturnal oxygen saturation 
(<93%) and lowest nocturnal oxygen saturation 
(<78%) [101]. Similarly, the risk of myocardial in-
farction at night (between midnight and 6 a.m.) is 
significantly higher in OSA patients than in non-
OSA subjects, indirectly indicating a possible inter-
relation [102]. Supporting the deleterious link, 
large-scale prospective studies based on general 
population cohorts demonstrated higher all-cause 
mortality in untreated SDB patients, particularly in 
the most severe cases [103–105]. However, a more 
recent analysis of the Sleep Heart Health Study, 
with longitudinal data after an 8.7-year follow-up, 
did not demonstrate an association of OSA with in-
cident coronary artery disease after adjusting for 
other risk factors. The risk of coronary artery dis-
ease was slightly increased in OSA patients younger 
than 70 years and in patients with severe OSA (AHI 
>30/h) [16]. The lack of a general association be-
tween SDB and coronary artery disease in the Sleep 
Heart Health Study may be explained in part by the 
cohort’s characteristics: predominantly elderly pa-
tients with a mean age of 62 years in whom risk fac-
tors other than OSA may play a more important role 
in an unfavourable prognosis, female prevalence, 
high frequency of asymptomatic forms (which may 
be disputable), etc. 
Nevertheless, the body of literature addressing the 
role of OSA as an independent risk factor for coro-
nary artery disease is constantly growing [106]. One 
supporting clue is the fact that OSA is inde-
pendently associated with subclinical coronary ath-
erosclerosis, measured as coronary calcification in 
computed tomography [107], and there is also a 
higher prevalence of noncalcified occlusive athero-
sclerotic plaques in OSA patients. In addition, data 
on the effects of PAP therapy are promising; it ap-
pears to reduce the risk of recurrent ischaemic 
events and the necessity of revascularisation proce-
dures [108, 109]. 
Sleep-disordered breathing and heart 
rhythm disorders 
Bradyarrhythmias, including sinus and atrioventric-
ular block of different degrees, are found in 10 to 
50% of OSA patients, depending on the population 
and diagnostic criteria applied [110]. On the other 
hand, the rate of SDB in patients with implanted 
pacemakers is up to 50% [111]. Moreover, CPAP 
therapy has a protective effect against bradyarrhyth-
mias, as demonstrated in prospective studies [112, 
113]. Therefore, sleep apnoea is currently consid-
ered to be one of the reversible causes of brady-
arrhythmias, and a sleep study is recommended be-
fore pacemaker implantation [114, 115]. 
OSA prevalence was two-fold higher in patients 
with atrial fibrillation than in a general cohort of pa-
tients referred to the cardiology clinic (after adjust-
ment for the main risk factors) [21]. In addition, 
OSA was associated with a higher risk of recurrent 
atrial fibrillation after radiofrequency ablation pro-
cedures [116], as well as atrial fibrillation onset in 
the postoperative period after coronary artery by-
pass grafting (odds ratio 1.89, 95% CI 1.24–2.80; p 
= 0.003) [117]. Although the available data suggest 
a strong relationship between atrial fibrillation and 
OSA, further studies are required to make definitive 
conclusions. 
Pathological mechanisms linking sleep-
disordered breathing and cerebro- and 
cardiovascular diseases – a bidirectional 
interaction 
A variety of underlying SDB-specific pathophysio-
logical mechanisms linking SDB with cerebro- and 
cardiovascular morbidity have been identified (fig. 
1). 
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Figure 1: Overview of SDB-spe-
cific pathophysiological mecha-
nisms linking SDB with cerebro- 
and cardiovascular morbidity – 
a bidirectional crosstalk. 
 
 
 
Common key features in all types of SDB may con-
tribute to future cerebro- and cardiovascular dis-
eases: intermittent hypoxaemia, intermittent in-
creases in carbon dioxide partial pressure and recur-
rent arousals. Moreover, unsuccessful respiratory 
efforts against obstructed upper airways in OSA 
also cause intrathoracic pressure swings, potentially 
affecting intrathoracic organs and blood flow to-
wards the heart and the brain. These phenomena can 
initiate physiological and pathophysiological reac-
tions that promote the development of cerebro- and 
cardiovascular sequelae. 
1. Intermittent hypoxaemia is one of the major path-
ophysiological features that can occur whenever 
respiration is impaired. It leads to chemoreflex 
activation and oxidative stress. Additionally, in-
termittent hypoxaemia is associated with in-
creased arrhythmogenesis, a potential cause of 
sudden cardiac death; severity of hypoxemia has 
been shown to predict sudden cardiac death in 
OSA patients [101]. Moreover, blood pressure 
and heart rate surges during apnoeas (see below) 
can increase myocardial oxygen demand that, 
against the background of hypoxaemia, can cause 
relative myocardial ischaemia and potentially 
threatening heart rhythm disorders. Furthermore, 
intermittent hypoxaemia with oxidative stress 
triggers systemic inflammation, which can pro-
mote the genesis of atherosclerotic plaques, and 
potentially contributes to the development of 
plaque vulnerability and rupture. Severe hypox-
aemia, with impaired chemosensitivity and local 
changes in the cerebral circulation, can also cause 
cerebral ischaemia, increasing the risk of stroke / 
transient ischaemic attack and their sequelae [50, 
118–120]. 
2. Recurrent arousals primarily result in activation 
of the sympathetic nerve system. This acutely 
leads to intermittent heart rate and blood pressure 
surges and to a secondary activation of the renin-
angiotensin-aldosterone system, a known patho-
physiological mechanism in arterial hyperten-
sion. Another consequence of recurrent arousals 
are baroreflex impairment and autonomic dys-
function, namely fluctuations with abrupt rises in 
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parasympathetic activity (during apnoeas) chang-
ing into sympathetic overactivity (at the end of 
apnoeas) during sleep, and sustained sympathetic 
hyperactivity during wakefulness [121, 122]. 
This manifests as a reduced heart rate variability 
that, in turn, is a known independent predictor of 
cardiovascular morbidity and mortality. Meta-
bolic changes, including hyperlipidaemia and in-
sulin resistance caused by oxidative stress and 
sympathetic overactivity, can further contribute 
to the cardiovascular consequences [24]. 
3. Intrathoracic pressure fluctuations intensify 
chemo- and baroreflex activation. They also lead 
to increased venous return and changes in heart 
preload and afterload resulting in myocardial re-
modelling. Both right and left heart ventricular 
remodelling, right and left ventricular hypertro-
phy, myocardial fibrosis, and left and right ven-
tricular diastolic dysfunction are associated with 
higher arrhythmogenesis and cardiovascular risk. 
Intrathoracic pressure swings are also transmitted 
to the vasculature and may cause endovascular 
sheer stress and endothelial dysfunction. Endo-
thelial dysfunction, together with intermittent hy-
poxaemia, triggers more rapid atherosclerosis de-
velopment and arterial remodelling. In the multi-
centre HeartBEAT study, moderate-to-severe hy-
poxaemia, defined as an oxygen desaturation in-
dex >24.6/h, was associated with a more pro-
found decline in endothelial function assessed by 
flow mediated vasodilation [123]. The relation-
ship with oxygen desaturation index was more ro-
bust than the one with AHI. In post-stroke pa-
tients, AHI and severity of nocturnal hypoxemia 
independently increase the risk for arterial stiff-
ness (odds ratio 5.98, 95% CI 1.11–41.72), even 
after controlling for age, sex, BMI, hypertension, 
and diabetes mellitus [124]. 
4. All three SDB features may enhance the hyper-
coagulatory state found in sleep apnoea patients, 
which possibly augments the risk of acute vascu-
lar complications (acute coronary syndrome, is-
chaemic cerebrovascular events) [125–127]. In 
particular, activation of the prothrombotic sys-
tem, and alterations of fibrinolysis were found in 
patients with OSA (an increase in fibrinogen lev-
els [125], increase in plasminogen activator in-
hibitor-1, tissue-type plasminogen activator [50, 
125, 128, 129], etc.). 
Despite the afore summarised evidence of a causal 
relationship between SDB and cerebro- and cardio-
vascular events and comorbidities, one may assume 
that the higher cerebro- and cardiovascular risk in 
OSA patients is just a cumulative effect of shared 
risk factors, such as obesity, male gender, hyperten-
sion, hyperlipidaemia, etc. Intriguingly, however, 
the relationship between SDB and cerebro- and car-
diovascular morbidities seems to be more complex 
and bidirectional. Specifically, cerebro- and cardio-
vascular diseases themselves might contribute to the 
development or aggravation of SDB. In stroke pa-
tients, there is a significant reduction in SDB prev-
alence and severity from the acute to the subacute 
stroke phase, indicating a direct impact of acute 
brain damage (and its complications) on SDB [7]. 
In recent years, a novel concept elucidating the de-
velopment of SDB in congestive heart failure and 
other states that are associated with fluid retention 
(renal disease, hypoproteinaemia, treatment re-
sistant hypertension, and others) has been intro-
duced [130, 131]. In fact, this hypothesis adds some 
new insights to the traditional understanding and 
helps to put some pieces of the puzzle together. Ac-
cording to this theory, the recumbent position and 
the associated changes in gravity in patients with 
congestive heart failure (at night / during sleep) is 
associated with a fluid shift from the legs to the up-
per body, including lungs, neck and upper airway. 
This was confirmed in a series of high-level experi-
ments with the application of lower body positive 
pressure in both healthy individuals and congestive 
heart failure patients. This intervention led to a rapid 
increase in neck circumference and increased col-
lapsibility of the upper airways (precisely confirmed 
with magnetic resonance imaging and plethysmo-
graphic measurements), thus increasing the risk of 
OSA development. On the other hand, fluid shifts 
from the legs leads to an increase in venous return 
to the heart, thus increasing pulmonary capillary 
wedge pressure and pulmonary congestion. This 
stimulates pulmonary irritant receptors, and as a 
consequence, causes hyperventilation and a reduc-
tion in CO2 partial pressure below the apnoea 
threshold. The latter is crucial for ventilatory control 
during sleep. Against the background of impaired 
chemosensitivity that is commonly observed in con-
gestive heart failure patients, even slight changes 
can cause significant fluctuations in ventilation. 
Changes in the severity of fluid retention and pe-
ripheral oedema can lead to the modulation of the 
degree of CSA and be responsible for the predomi-
nance of either OSA or CSA in patients with con-
gestive heart failure. A bidirectional interaction be-
tween sleep apnoea and congestive heart failure is 
also suggested by the beneficial effects of cardiac 
resynchronisation therapy and heart transplantation 
on SDB, particularly with respect to central sleep 
apnoea [132–134]. 
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Diagnostic approach – always consider 
sleep-disordered breathing in cerebro- 
and cardiovascular patients 
Because of the higher prevalence of SDB in popu-
lations with cerebro- and cardiovascular diseases 
and their potential detrimental impacts, it is crucial 
to consider SDB as a potentially modifiable cardio-
vascular risk factor, especially given the availability 
of treatment options [11]. The recognition of a po-
tential role of SDB and its association with car-
dio/cerebrovascular diseases is reflected in current 
guidelines for the management of specific diseases 
such as stroke, arterial hypertension and heart fail-
ure [4–6]. However, despite these guidelines and the 
growing evidence of a strong bidirectional relation 
between sleep apnoea and cerebro/cardiovascular 
diseases, the majority of cases still remain undiag-
nosed [1, 16, 70, 102]. Therefore, the routine imple-
mentation of diagnostic approaches and application 
of reliable and valid screening tools is important, 
although the results and further treatment strategies 
should be treated with caution since a general cardi-
ovascular benefit has not yet been confirmed for all 
comorbidities in recent trials. 
Exploration of the patient’s history for clinical signs 
and symptoms of SDB and typical physical risk fac-
tors such as obesity and relevant retrognathia should 
always be the first step (fig. 2). A more comprehen-
sive SDB evaluation should follow in patients at 
risk. Patients should be asked more detailed ques-
tions regarding typical sleep-related and daytime 
signs and symptoms. These include snoring, wit-
nessed apnoeas, dyspnoea/choking during sleep, re-
petitive awakenings, dry mouth and nocturnal 
sweating. Daytime manifestations include excessive 
daytime sleepiness, fatigue, morning (or nocturnal) 
headache, cognitive impairment and irritability, etc. 
The clinical manifestations of CSA may be less ev-
ident and are usually dominated by the underlying 
disease (e.g., heart failure). Fatigue, nonrestorative 
sleep, hyperventilation and disrupted sleep are fre-
quently found [135]. 
Questionnaires evaluating the likelihood of clini-
cally relevant SDB can be helpful, combined with a 
physical examination looking for features abetting 
SDB. For primary screening, there are various ques-
tionnaires that can be easily incorporated into rou-
tine clinical visits, such as the commonly used Ber-
lin Sleep Apnea questionnaire, STOP-BANG ques-
tionnaire (and its modifications), and the recently 
introduced NoSAS-Score for OSA screening and 
Epworth sleepiness scale for daytime sleepiness as-
sessment [136, 137]. However, recently published 
data have raised new issues regarding appropriate 
questionnaire screening tools in specific cohorts. 
For example, stroke patients usually demonstrate 
lower or normal values on the Epworth Sleepiness 
Scale and Berlin questionnaire as compared with 
non-stroke patients with SDB [7, 138]. The same is 
true for patients with atrial fibrillation or congestive 
heart failure [139, 140]. Such “masked” manifesta-
tion can lead to a significant underestimation of 
SDB burden in special conditions and potentially 
prevent timely treatment. For example, the Hyp-
noLaus study has shown that the conventional clin-
ical symptoms/signs are less predictive for the pres-
ence of SDB than the NoSAS score (a quantitative 
predictive scale for SDB probability evaluation that 
includes the following parameters: obesity, neck 
circumference, age, snoring and gender) [2, 136]. 
Thus, although disputed by some authors [137, 
141], the common screening questionnaires seem to 
be inappropriate in some cohorts, and more differ-
entiated diagnostic algorithms and individualised 
approaches are required [64]. 
Manifestations of SDB are heterogeneous in popu-
lations with differing comorbidities. Recently, a 
concept of different clinical phenotypes or “differ-
ent clinical faces” of SDB/OSA has been suggested 
[142]. A collaborative Icelandic-American group 
identified three main clusters by grouping them ac-
cording to the complaints/symptoms and comorbid-
ities as follows: “disturbed sleep group”, “mini-
mally symptomatic group” and the most prevalent 
“excessive daytime sleepiness group” consisting of 
32.7%, 24.7%, and 42.6%, respectively, of the Ice-
landic cohort studied [142]. The probability of 
comorbid cardiovascular diseases differed between 
the subtypes, being lowest in the third cluster – the 
sleepiest one. Intriguingly, the probability of cere-
bro- and cardiovascular pathology was highest in 
the second group, which has minimal symptoms, 
and thus, according to current practice, is the last to 
be referred to sleep centres for specific SDB therapy 
[142, 143]. The heterogeneity of clinical manifesta-
tions might also be associated with different re-
sponses to therapy and/or adherence to treatment, 
potentially serving as a tool to choose treatment. 
Therefore, objective diagnostic approaches should 
be applied at a low threshold for specific subgroups 
of patients, such as those with high estimated cere-
bro- or cardiovascular risks. In these cases, special-
ised instrumental examination may be considered 
the first step regardless of the presence of the clini-
cal manifestations. 
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Figure 2: Sugges-
tion for a simple 
three-step algo-
rithm for the evalu-
ation of sleep-disor-
dered breathing 
(SDB). 
BMI = body mass in-
dex; MSLT = multi-
ple sleep latency 
test; MWT = 
maintenance of 
wakefulness text; 
OSA = obstructive 
sleep apnoea 
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Based on American Academy of Sleep Medicine 
(AASM) criteria, four categories of diagnostic de-
vices are distinguished (table 2), with attended ob-
served video polysomnography as the “gold stand-
ard”. However, simple two-channel devices, includ-
ing nocturnal oximetry and recording of the airflow, 
may be sufficient for screening and should be pre-
ferred to nocturnal oximetry only, which may miss 
at least one third of all relevant SDB. Cardiorespir-
atory polygraphy is usually referred to as a screen-
ing test, but it may be sufficient to establish the di-
agnosis in individuals with high clinical suspicion 
of SDB, as shown in recent studies reporting ac-
ceptable results for SDB identification by portable 
polygraphy in patients with cardiovascular comor-
bidities [144]. 
 
Table 2: Types of diagnostic tool (according to the American Academy of Sleep Medicine classification). 
Monitor Type of the diagnostic 
tool 
Parameters recorded Benefits Disadvantages 
Type I Attended, in-lab standard 
full (video) polysomnog-
raphy 
7 channels 
including EEG, chin EMG, 
ECG, airflow, (chest, ab-
dominal) respiratory ef-
forts, oximetry, leg move-
ments, position 
– “Gold standard” 
– Sleep structure as-
sessment 
– Opportunity to per-
form interventions 
– Costly 
– Labour-intensive 
– Discomfort for the 
patient 
– Experienced and 
trained personnel 
(technician) 
– In-lab 
Type II Unattended full (video) 
polysomnography 
7 channels 
including EEG, chin EMG, 
heart rate or ECG, airflow, 
(chest, abdominal) respira-
tory efforts, oximetry, leg 
movements, position 
– Sleep structure as-
sessment 
– Both in the lab and 
at home 
– Costly 
– Labour-intensive 
– Discomfort for the 
patient 
– No opportunity to 
perform interven-
tions 
– Experienced and 
trained personnel 
(technician) 
Type III Polygraphy, limited chan-
nel devices (portable) 
4 channels including ven-
tilation or airflow (at least 2 
channels of respiratory 
movements, or airflow and 
respiratory movements), 
oximetry, heart rate or 
ECG, position, leg move-
ments (optional) 
– Inexpensive 
– Easy to perform 
– More comfortable 
– Portable (home) 
monitoring 
– Higher risk of false-
positive and false-
negative results 
Type IV Limited channel devices 
(screening) 
1 or 2 channels, usually oxi-
metry and heart rate or air-
flow 
– Inexpensive 
– Easy to perform 
(screening) 
– More comfortable 
– Portable, home 
monitoring 
– Higher risk of false-
positive and false-
negative results 
ECG = electrocardiogram; EEG = electroencephalogram; EMG = electromyogram 
 
One of the most relevant controversial issues is the 
choice of scoring criteria for sleep-associated res-
piratory events, independent of the diagnostic de-
vice used, since different recommended rules have 
been implemented in clinical practice and research 
during the last two decades. This may cause signif-
icant differences in the number of recorded respira-
tory events and, thus, the prevalence and severity of 
SDB. In a cohort of heart failure patients, a differ-
ence of 4.6 events per hour was established in AHI 
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scoring according to AASM “recommended” and 
“alternative” rules, leading to a significant change 
in the detected SDB prevalence (29% vs 46%, 
p<0.001, based on an AHI 15/h) [145]. 
Currently, various alternative diagnostic tools are 
being developed, including portable, one-channel, 
non-contact devices (based on acoustic or bioradio-
location signals, etc.) [146, 147]. However, their 
utility in comorbid states has not yet been verified, 
although they appear to be promising screening de-
vices and tools for long-term and repeated monitor-
ing. 
Conclusion 
SDB is associated with cerebro- and cardiovascular 
diseases. Accumulating data provide new insights 
into the underlying mechanisms and need for novel 
management approaches. Undoubtedly, a wider im-
plementation of screening tools is required, in par-
ticular in patients at high risk for cerebro- and/or 
cardiovascular diseases, as well as better application 
of preventive and therapeutic approaches. At pre-
sent, some issues remain controversial, including 
the choice of diagnostic criteria and tools, the bene-
fits of PAP therapy in some populations, the para-
doxical effects of sleep apnoea in certain cohorts 
(e.g., preconditioning effects of sleep apnoea-asso-
ciated intermittent hypoxaemia), etc.. These ques-
tions can be answered in multicentre trials and in 
large multidisciplinary collaborative research pro-
jects (e.g., the International Collaboration of Sleep 
Apnea Cardiovascular Trialists, INCOSACT, SAS-
CARE, eSATIS [97, 98, 148] that could facilitate 
the promotion of research ideas, standardise proce-
dures and regulations while advancing our scientific 
understanding on the role of SDB in cardiovascular 
morbidity and mortality. 
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